Back to VRNAView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Chronic Obstructive Pulmonary Disease
View Full LandscapeDrug Information
Target Indication
Chronic Obstructive Pulmonary Disease
Clinical Trial
NCT07016412Last updated: 12/13/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
EnsifentrinePhase 3
Chronic Obstructive Pulmonary Disease
Ensifentrine 3 mg twice dailyPhase 3
COPD
Nebulized Ensifentrine Suspension; 3 mgPhase 2
Non-cystic Fibrosis Bronchiectasis
Glycopyrrolate (85 μg)Phase 2
Chronic Obstructive Pulmonary Disease
Part A: RPL554Phase 2
Pulmonary Disease, Chronic Obstructive
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts